According to a recent phase 3 clinical program consisting of two induction trials (U-EXCEL and U-EXCEED) and one maintenance trial (U-ENDURE), upadacitinib is a promising therapy for Crohn’s disease. Patients with moderate-to-severe Crohn’s disease were randomly assigned to receive either upadacitinib or placebo once daily for 12 weeks, followed by upadacitinib or placebo once daily for 52 weeks for those who responded to the initial treatment. A significantly higher proportion of patients in the upadacitinib groups achieved clinical remission compared with the placebo group. However, herpes zoster infections occurred more frequently in the upadacitinib groups, and hepatic disorders and neutropenia were more frequent in the 30 mg upadacitinib group.

To know more: About the original article click here.